Commonwealth Equity Services, LLC Nektar Therapeutics Transaction History

Commonwealth Equity Services, LLC

$77.2 Billion
Q3 2025

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Oct 23, 2023	SELL	$0.51 - $1.05 $51 - $105	-100 Reduced 0.78%	12,702 $8,000
Q2 2023 Aug 10, 2023	SELL	$0.53 - $1.03 $2,439 - $4,741	-4,603 Reduced 26.45%	12,802 $7,000
Q1 2023 May 11, 2023	SELL	$0.64 - $3.15 $32 - $157	-50 Reduced 0.29%	17,405 $12,000
Q4 2022 Feb 07, 2023	SELL	$2.03 - $4.28 $6,696 - $14,119	-3,299 Reduced 15.9%	17,455 $39,000
Q3 2022 Nov 14, 2022	SELL	$3.04 - $5.14 $152 - $257	-50 Reduced 0.24%	20,754 $66,000

Q2 2022 Jul 19, 2022	SELL	$3.17 - $6.17 $8,559 - $16,659	-2,700 Reduced 11.49%	20,804 $79,000
Q1 2022 May 04, 2022	SELL	$4.16 - $13.72 $1,867 - $6,160	-449 Reduced 1.87%	23,504 $126,000
Q4 2021 Jan 31, 2022	SELL	$10.83 - $18.41 $67,395 - $114,565	-6,223 Reduced 20.62%	23,953 $323,000
Q3 2021 Oct 29, 2021	BUY	$13.07 - $18.84 $48,633 - $70,103	3,721 Added 14.07%	30,176 $541,000
Q2 2021 Aug 11, 2021	BUY	$16.52 - $20.4 $3,849 - $4,753	233 Added 0.89%	26,455 $453,000
Q1 2021 May 04, 2021	BUY	$16.56 - $25.46 $16,145 - $24,823	975 Added 3.86%	26,222 $524,000
Q4 2020 Feb 11, 2021	SELL	$15.77 - $19.03 $6,765 - $8,163	-429 Reduced 1.67%	25,247 $429,000
Q3 2020 Nov 05, 2020	SELL	$16.59 - $24.79 $29,198 - $43,630	-1,760 Reduced 6.41%	25,676 $425,000
Q2 2020 Aug 12, 2020	BUY	$16.86 - $23.44 $14,061 - $19,548	834 Added 3.14%	27,436 $635,000
Q1 2020 May 11, 2020	SELL	$14.47 - $27.96 $18,159 - $35,089	-1,255 Reduced 4.51%	26,602 $474,000
Q4 2019 Feb 05, 2020	SELL	$15.87 - $23.12 $48,086 - $70,053	-3,030 Reduced 9.81%	27,857 $601,000
Q3 2019 Oct 30, 2019	BUY	$16.91 - $36.27 $68,891 - $147,763	4,074 Added 15.19%	30,887 $562,000
Q2 2019 Jul 19, 2019	BUY	$31.0 - $36.3 $84,878 - $99,389	2,738 Added 11.37%	26,813 $954,000
Q1 2019 May 13, 2019	BUY	$31.58 - $46.35 $186,069 - $273,094	5,892 Added 32.4%	24,075 $808,000
Q4 2018 Feb 11, 2019	BUY	$30.43 - $56.65 $56,691 - $105,538	1,863 Added 11.42%	18,183 $597,000
Q3 2018 Nov 06, 2018	BUY	$46.46 - $68.49 $133,014 - $196,086	2,863 Added 21.28%	16,320 $994,000
Q2 2018 Jul 31, 2018	BUY	$46.25 - $104.45 $205,951 - $465,115	4,453 Added 49.46%	13,457 $657,000
Q1 2018 May 14, 2018	BUY	$57.4 - $108.44 $204,573 - $386,480	3,564 Added 65.51%	9,004 $956,000
Q4 2017 Feb 12, 2018	BUY	$23.02 - $60.5 $125,228 - $329,120	5,440	5,440 $325,000

Others Institutions Holding NKTR

# of Institutions

Shares Held

15.6M

Call Options Held

Put Options Held

Black Rock Inc. New York, NY

15.2M
Shares

$859 Million
0.0% of portfolio
Nuveen Asset Management, LLC Chicago, IL

327K
Shares

$18.5 Million
0.0% of portfolio
Vista Wealth Management Group, LLC

51.5K
Shares

$2.92 Million
0.0% of portfolio
Frontier Wealth Management LLC Kansas City, MO

12K
Shares

$680,160
0.0% of portfolio
Ropes Wealth Advisors LLC Boston, MA

11.6K
Shares

$656,354
0.0% of portfolio

View Full List

About NEKTAR THERAPEUTICS

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $10.6B
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

More about NKTR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Commonwealth Equity Services, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Commonwealth Equity Services, LLC with notifications on news.

Account